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Abstract
The use of bisphosphonates (BPs) has proven effective in the treatment of bone-related diseases, despite the potential 
risk of developing osteonecrosis of the jaw (ONJ). So far, results for the treatment of ONJ have not been satisfac-
tory. In our study, we have treated two patients diagnosed with ONJ. In addition to local treatments a hydrogel was 
applied, with promising results. The fistulae disappeared 2-3 weeks into the treatment. After a six-month follow-up 
period there has been no sign of recurrence. The extent of maxillary bone exposure has diminished notably, although 
not entirely disappeared. In all cases, the patients exhibit no other symptoms (they suffer from no pain or swelling or 
functional impotence). For this reason we believe this protocol might be useful in the case of patients who suffer from 
pain and fistulation secondary to BP-associated ONJ to improve the state of their lesions until definitive treatment 
can be undertaken. 
Although these findings are not conclusive, given that we are reporting data on two patients only, we believe that 
this might be an alternative treatment in refractory cases where other therapies are counter-indicated. A controlled 
randomized and prospective study would be required to confirm our findings.
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Introduction
Bisphosphonates (BPs) are powerful inhibitors of  os-
teoclast activity, and via interaction with these cells bring 
about a reduction in bone resorption. In the case of 
patients suffering from cancer, the most frequently used 
BPs are pamidronate and zoledronic acid; commonly 
used  in the treatment of malignant hypercalcemia, mul-
tiple myeloma and bone metastases from solid tumours 
(breast, prostate and lung) in association with specific 
antineoplastic therapy. 
Some patients suffering from multiple myeloma, breast 
or prostate cancer under treatment with pamidronate or 
intravenous zoledronic acid have exhibited a clinical pic-
ture of intraoral bone necrosis, spontaneously produced 
after dental extraction or oral trauma.  These patients had 
not been treated with head or neck radiotherapy. These 
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oral lesions are known as BP-associated osteonecrosis of 
the jaw (ONJ), and are a new significant complication in 
BP-associated adjuvant treatment. 
So far, their treatment has been controversial since there 
are different patterns and they do not respond to medical 
and/or surgical treatments. 
In this paper we propose a possible conservative treatment 
of ONJ lesions, especially of cutaneous fistulae, by means 
of local treatments and the application of a hydrogel with 
alginate (Nu-Gel®). 
Clinical Cases
BF-associated ONJ treatment was undertaken on two 
patients transferred from the Oncological Department 
to the Stomatological, Oral and Maxillofacial Surgery 
Department of the Hospital Universitario Insular de Las 
Palmas de Gran Canaria. Both suffered from oral bone 
exposure and fistulae in the submentonian region. Since 
there was no agreement concerning adequate treatment, a 
conservative treatment was administered by the following 
protocol: 
1. Oral antibiotherapy: 
• Amoxicillin/Clavulanic acid 1000/62.5 milligrams (Aug-
mentine Plus®), 2 tablets/day for 30 days.
• Metronidazole 250 milligrams (Flagyl®),  2 tablets every 
8 hours, for 10-20 days.
2. Oral rinsing with  0.12% chlorhexidine mouthwash 
(Bexident Gums®), 3-4 times a day.
3. Local treatment of fistulae by means of:
• Rinsing lesions with physiological serum.
• 4 ml irrigation solution for the intravenous perfusion of 
ciprofloxacin 2 mg/ml (Normon) 
• Application of hydrogel with alginate (Nu-Gel®). 
This treatment was performed daily until the fistulae 
healed. Later weekly check-ups were carried out during 
the follow-up period. 
- Case 1
The patient was a 47 year-old male smoker, diagnosed 20 
months earlier with poorly differentiated adenocarcinoma 
of the prostate with bone involvement. Under treatment 
with zoledronate for 20 months, with a total dose received 
of 80 mg.  With a history of tooth 35 radicular remains 
removal 12 months before, which despite treatment did 
not heal despite the antibiotic treatment prescribed. He 
suffered from mucous ulceration, halitosis, bad taste in 
mouth, fever, nausea, exposed bone, mobility of tooth 
34 and fistulae in the area surrounding tooth 44 and in 
the submentonian region.  (Figures 1-4). Biopsy with no 
evidence of  carcinomatous infiltration, with acute nons-
pecific chronic inflammatory signs. 
Treatment was initially administered by the protocol des-
cribed above, with local daily treatment from Monday to 
Saturday over a period of two weeks. The hydrogel was 
injected into the cutaneous fistula until its intraoral exit 
was verified on both sides. After two weeks the fistulae had 
Fig. 1. Exposed bone in the area surrounding tooth 34.
Fig. 2. Mucous fistulae.
Fig. 3. Fistula in the submentonian region.
Fig. 4. Orthopantomography of the case 1.
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healed. Currently, after a 7-month follow-up period, there 
has been no sign of fistulae recidivation and, although 
the bone is still exposed in the mouth, there is no pain or 
suppuration. The prosthesis does not cause any discomfort 
and he can eat without difficulty. He still smokes. He is 
not taking antibiotics and is reinforcing his oral hygiene 
with a chlorhexidine mouthwash. 
- Case 2
A 42-year-old female diagnosed 7 years previously with 
infiltrating ductal carcinoma of the left breast. She also 
suffers from bone, hepatic and pleuropulmonary metas-
tasis. She was treated with zoledronate (for 18 months, 
with a total dose received of 72 mg). She reported that 
6 months ago she suffered from pain and swelling in the 
area surrounding tooth 45, with no predisposing factors. 
Later her face swelled and she suffered from very fetid 
suppuration in the right mandibular region. Two months 
prior to coming to our department she spontaneously lost 
tooth 45. On examination, bone exposure was revealed in 
an area close to teeth 45-46. Clinically, she also suffered 
from paresthesiae, suppuration and fistula in the subman-
dibular region which, though not painful, made eating 
difficult. (Figures 5-7).
Bone gammagraphy images reveal in relation to the 
ONJ diagnosis a focal pathological accretion in the right 
hemimandible. After three weeks of  treatment by the 
protocol described the fistula had healed. Currently, after 
a six-moth follow-up period, the patient reports clinical 
improvement, the fistula has not recurred and, although 
the bone is still exposed in the mouth, there is no pain 
and she has less difficulty in eating. She continues with 
intermittent antibiotic cycles (Amoxicillin/Clavulanic acid) 
rinsing her mouth with chlorhexidine. 
Discussion
BF-associated ONJ is a recently described entity with 
numerous series and cases published (1-3). 
The panels of experts constituted so far, representing  the 
American Dental Association, the American Association 
of Oral and Maxillofacial Surgeons, the American Society 
for Bone and Mineral Research, the American Academy of 
Oral Medicine and the Spanish expert panel (4-8) agree on 
the fact that the exact incidence and risk posed by ONJ has 
not yet been established, and that there is no specific guide 
regarding the handling of patients treated with BP. 
Many clinical protocols have been proposed, with irregular 
results. Radical surgical resections have not been effective and 
have even worsened the course of the disease. (2, 6, 9-11).
Surgical debridement has not been successful either re-
garding the eradication of necrotic bones, and hyperbaric 
oxygen therapy has not been able to limit the progress of 
the disease. (1, 2, 6, 12, 13). Most authors, consequently, 
propose strictly conservative treatments when dealing 
with ONJ. (1, 14).
In our patients’ case, we have followed the recommenda-
tions of the expert committees (4-8) regarding the admi-
nistration of  antiseptic mouthwashes, antibiotherapy by 
general route, but to this strategy we have added  irrigation 
with antibiotics (ciprofloxacin) and the local application 
of a hydrogel. Nu-Gel® is an amorphous hydroactive gel 
that contains sodium alginate. This hydrogel is normally 
indicated for the debridement and reduction of ulcer exu-
dates and for the treatment of chronic ulcers in all stages 
of healing. On the fistulae we have used the method des-
cribed above, with successive applications of physiological 
serum, irrigation with ciprofloxacin in order to achieve a 
DNA gyrase enzyme-inhibiting bactericidal effect against 
a wide range of bacteria (15) and, finally, Nu-Gel is applied 
directly inside the fistula through the tube nozzle. 
Fig. 7. Orthopantomography of the case 2.
Fig. 5. Bone exposure in an area close to teeth 45-46.
Fig. 6. Fistula in the submandibular region.
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Oral and cutaneous fistulae disappeared after 2-3 weeks 
of treatment. After a six-month follow-up period there has 
been no sign of recurrence. Although it has not entirely 
disappeared, the extent of maxillary bone exposure has 
notably diminished. In no cases, do the patients exhibit 
any other symptoms, such as pain, swelling or functional 
impairment. For this reason, we believe this protocol 
might be useful in the case of patients who suffer from 
pain and fistulation secondary to BP-associated ONJ to 
improve the state of their lesions until definitive treatment 
can be undertaken. 
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